← Back to Search

GC4711 + SBRT for Pancreatic Cancer

Phase 2
Waitlist Available
Research Sponsored by Galera Therapeutics, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up from randomization up to 3 years

Summary

This trial is testing a new drug called GC4711 to see if it can improve the results of a precise radiation therapy for patients whose cancer cannot be easily removed by surgery. The goal is to find out if adding GC4711 makes the radiation treatment more effective. This could help patients with difficult-to-remove cancers live longer.

Eligible Conditions
  • Pancreatic Cancer
  • Stereotactic Body Radiation Therapy

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~from randomization up to 3 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and from randomization up to 3 years for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Overall Survival
Secondary study objectives
Median Progression Free Survival after SBRT Completion per RESIST 1.1

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: Arm A Active GC4711Experimental Treatment1 Intervention
Group II: Arm B PlaceboPlacebo Group1 Intervention

Find a Location

Who is running the clinical trial?

Galera Therapeutics, Inc.Lead Sponsor
16 Previous Clinical Trials
1,173 Total Patients Enrolled
Jon Holmlund, MDStudy ChairChief Medical Officer
6 Previous Clinical Trials
213 Total Patients Enrolled

Media Library

Drug GC4711 Clinical Trial Eligibility Overview. Trial Name: NCT04698915 — Phase 2
Pancreatic Cancer Research Study Groups: Arm A Active GC4711, Arm B Placebo
Pancreatic Cancer Clinical Trial 2023: Drug GC4711 Highlights & Side Effects. Trial Name: NCT04698915 — Phase 2
Drug GC4711 2023 Treatment Timeline for Medical Study. Trial Name: NCT04698915 — Phase 2
~39 spots leftby Dec 2025